| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 41 | Composite of all below metrics; sustained negative EPS, collapsing valuation, extreme volatility | 6-12M |
| Growth Sustainability & Moat | C- | 48 | Revenue growth only 3.82% YoY; hyper-growth flagged but offset by -1.95 EPS; weak structural moat in commoditized cannabis | 6-12M |
| Valuation & Safety (Pre-Penalty) | D | 38 | No meaningful P/E (negative EPS); price at 52-week low ($3.67); 52W drawdown -30.85%; market cap $469M on slowing growth | 1-3M |
| Institutional & Smart Money Flow | D | 35 | Analyst consensus scattered (median $2.00–$9.25 across sources); recent downgrades reflect cautious outlook; limited institutional support visible | 1-3M |
| Volatility & Drawdown Risk | D- | 32 | Beta 1.95 (elevated); 52W range $3.67–$23.20 (532% span); -30.85% YTD return; 0.04 intraday swing (-0.99%) shows continued instability | 1-3M |
| Confidence Score | C | 52 | Data coverage: earnings date and recent fundamentals partially constrained; analyst dispersion high; structural cannabis headwinds well-documented | 6-12M |
| Penalty Overlay | F | 0 | Negative profitability (EPS -1.95), weak balance sheet flagged, no dividend; penalizes by ~15–20 points | 6-12M |
Tilray occupies the cannabis therapeutics / pharmaceutical crossover segment, a crowded and structurally challenged space. The "Pharmaceuticals" sector label masks underlying cannabis commodity dynamics: oversupply in Canada, regulatory fragmentation in the US, and persistent margin pressure. Comparable pure-play cannabis peers (Cronos, Canopy Growth) face similar headwinds. Tilray's 3.82% revenue growth trails inflation and most pharma subsectors, while operating at a loss. Its beta of 1.95 reflects both sector volatility and company-specific execution risk. The 52-week range of $3.67–$23.20 (532% span) underscores investor sentiment whipsaw and weak fundamental anchors.
| Horizon | Assessment | Key Driver |
|---|---|---|
| 1–3 Months | Cautionary; elevated downside risk. Price at 52W low signals capitulation, but technical support weak. Negative EPS and cash burn dynamics argue for defensive stance. Any near-term catalyst (M&A, US regulatory shift) could swing sentiment sharply, but not factored into base case. | Momentum exhaustion; technical support breakdown; earnings visibility poor |
| 6–12 Months | Structural headwinds persist. Revenue growth must accelerate meaningfully (to 8–10% minimum) to justify a recovery valuation. Profitability inflection currently absent from guidance. Macro cannabis sentiment remains weak, but US legalization upside is optionality. Long-term bull thesis requires transformational M&A or market-share gain; base case does not warrant accumulation yet. | Profitability path unclear; Cannabis policy tailwinds uncertain; M&A potential (binary) |
Wall Street Consensus (Current): Consensus price target of US$11.69 , though analysts have adjusted their fair value estimate from $8.50 to $9.25 . Recent data suggests 2 Wall Street analysts issued a 1-year TLRY price target with an average of $8.50, with a high of $10.00 and a low of $7.00 . This implies 113–188% upside from current levels, but analyst dispersion is elevated and recent commentary has grown increasingly cautious around revenue visibility and margin sustainability.
Note: Target ranges vary materially across sources ($7.25–$11.69). Some outlier models (e.g., StockScan, technical proxies) project 2026 fair value of $19.91 or higher, but these are not consensus Street views and carry significant uncertainty. Use consensus ($9.25–$11.69) with caution given recent downgrades and profit visibility constraints.
TLRY Stock Analysis & Forecast
Is TLRY a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
TLRY Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, TLRY shows balanced risk-reward characteristics.
Should You Buy TLRY Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in TLRY.